

University of Groningen

## Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension

Kwakernaak, A. J.; Roksnoer, L. C.; Heerspink, H. J. Lambers; van den Berg-Garrelts, I.; Lochorn, G. A.; Andres, J. H. van Embden; Klijn, M. A.; Kobori, H.; Danser, A. H. J.; Laverman, G. D.

*Published in:*  
 PLoS ONE

*DOI:*  
[10.1371/journal.pone.0169258](https://doi.org/10.1371/journal.pone.0169258)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
 Publisher's PDF, also known as Version of record

*Publication date:*  
 2017

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Kwakernaak, A. J., Roksnoer, L. C., Heerspink, H. J. L., van den Berg-Garrelts, I., Lochorn, G. A., Andres, J. H. V. E., ... Navis, G. J. (2017). Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial. *PLoS ONE*, 12(1), [e0169258]. <https://doi.org/10.1371/journal.pone.0169258>

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*


RESEARCH ARTICLE

# Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial

A. J. Kwakernaak<sup>1\*</sup>, L. C. Roksnoer<sup>2</sup>, H. J. Lambers Heerspink<sup>3</sup>, I. van den Berg-Garrelts<sup>2</sup>, G. A. Lochorn<sup>4</sup>, J. H. van Embden Andres<sup>5</sup>, M. A. Klijn<sup>5</sup>, H. Kobori<sup>6</sup>, A. H. J. Danser<sup>2</sup>, G. D. Laverman<sup>1,7</sup>, G. J. Navis<sup>1</sup>

**1** Department of Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands, **2** Department of Medicine, Division of Vascular Medicine and Pharmacology, Erasmus Medical Center, Rotterdam, The Netherlands, **3** Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands, **4** General Practitioner Practice Gorecht, Hoogezaand, The Netherlands, **5** General Practitioner Practice Boterdiep, Groningen, The Netherlands, **6** Department of Pharmacology, Kagawa University, School of Medicine, Miki, Kita District, Kagawa, Japan, **7** Department of Internal Medicine, Division of Nephrology, ZGT Hospital Almelo, Netherlands

\* [a.j.kwakernaak@hotmail.nl](mailto:a.j.kwakernaak@hotmail.nl)



**OPEN ACCESS**

**Citation:** Kwakernaak AJ, Roksnoer LC, Lambers Heerspink HJ, van den Berg-Garrelts I, Lochorn GA, van Embden Andres JH, et al. (2017) Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial. PLoS ONE 12(1): e0169258. doi:10.1371/journal.pone.0169258

**Editor:** Yoshitaka Isaka, Osake University Graduate School Of Medicine, JAPAN

**Received:** May 10, 2016

**Accepted:** December 11, 2016

**Published:** January 24, 2017

**Copyright:** © 2017 Kwakernaak et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** We are unable to upload our data set as this is prohibited by our agreement with our funding source (Novartis). However, all data are available upon request, in line with PLOS ONE requirements. Data will be available to all interested researchers in the same manner in which the authors accessed it. Data are from the HEALTH study whose authors may be contacted at [a.kwakernaak@umcg.nl](mailto:a.kwakernaak@umcg.nl).

## Abstract

### Aim

The combination of weight excess and hypertension significantly contributes to cardiovascular risk and progressive kidney damage. An unfavorable renal hemodynamic profile is thought to contribute to this increased risk and may be ameliorated by direct renin inhibition (DRI). The aim of this trial was to assess the effect of DRI on renal and systemic hemodynamics and on RAAS activity, in men with weight excess and hypertension.

### Methods

A randomized, double-blind, cross-over clinical trial to determine the effect of DRI (aliskiren 300 mg/day), with angiotensin converting enzyme inhibition (ACEi; ramipril 10 mg/day) as a positive control, on renal and systemic hemodynamics, and on RAAS activity (n = 15).

### Results

Mean (SEM) Glomerular filtration rate (101 (5) mL/min/1.73m<sup>2</sup>) remained unaffected by DRI or ACEi. Effective renal plasma flow (ERPF; 301 (14) mL/min/1.73m<sup>2</sup>) was increased in response to DRI (320 (14) mL/min/1.73m<sup>2</sup>, P = 0.012) and ACEi (317 (15) mL/min/1.73m<sup>2</sup>, P = 0.045). Filtration fraction (FF; 34 (0.8)%) was reduced by DRI only (32 (0.7)%, P = 0.044). Mean arterial pressure (109 (2) mmHg) was reduced by DRI (101 (2) mmHg, P = 0.008) and ACEi (103 (3) mmHg, P = 0.037). RAAS activity was reduced by DRI and ACEi. Albuminuria (20 [9–42] mg/d) was reduced by DRI only (12 [5–28] mg/d, P = 0.030).

**Funding:** This trial was supported by an unrestricted grant from Novartis to G.N. (ZCSPP100-ANL07T). G.N. received funding from Friesland health insurance company and Nutricia concerning the projects 'Lifestyle Geomapping Friesland' and 'Malnutrition in renal transplant recipients', respectively. H.L.H. is a consultant for and received honoraria from AbbVie, Astellas, Astra Zeneca, Boehringer Ingelheim, Janssen, and Merck. He has a policy that all honoraria are paid to his employer, University Medical Center Groningen. The specific roles of these authors are articulated in the 'author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** This trial was supported by an unrestricted grant from Novartis to G.N. (ZCSPP100-ANL07T). Trial medication was also provided by Novartis. G.N. received funding from Friesland health insurance company and Nutricia concerning the projects 'Lifestyle Geomapping Friesland' and 'Malnutrition in renal transplant recipients', respectively. H.L.H. is a consultant for and received honoraria from AbbVie, Astellas, Astra Zeneca, Boehringer Ingelheim, Janssen, and Merck. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors have no competing interests. There are no patents, products in development or marketed products to declare.

## Conclusions

In men with weight excess and hypertension, DRI and ACEi improved renal and systemic hemodynamics. Both DRI and ACEi reduced RAAS activity. Thus, DRI provides effective treatment in weight excess and hypertension.

## Trial Registration

Dutch trial register, registration number: 2532 [www.trialregister.nl](http://www.trialregister.nl)

## Introduction

The prevalence of weight excess has been steadily rising over the past decades and shows no sign of abating yet, thereby becoming a major global health problem of the 21st Century [1,2]. The association between weight excess and hypertension is widely recognized, and linked to an increased risk for long-term cardiovascular and renal damage [3–7]. The increased renal risk associated with weight excess and hypertension is only partly explained by the elevated blood pressure as such, and additional factors such as insulin resistance and an unfavorable renal hemodynamic profile have been implicated [8–11].

Weight excess is associated with distinct renal hemodynamic abnormalities, that are prominent in subjects with overt obesity, but already apparent in the overweight range, with an elevated filtration fraction (FF) as a common denominator [12]. The latter may reflect glomerular hypertension that contributes to long-term renal damage, as shown in animal experiments [13]. We previously reported on the consistent association between higher body mass index (BMI) and higher FF, and moreover, showed that higher FF is independently associated with worse long-term outcome in renal transplant recipients, supporting a role of higher FF as a renal risk factor in humans [14].

Blockade of the renin-angiotensin-aldosterone system (RAAS) reduces blood pressure and exerts specific renal hemodynamics effects, with a reduction in FF, and provides long-term renoprotection in patients with renal disease [15,16]. Accordingly, the renal hemodynamic actions of RAAS blockade may be of benefit especially in subjects with weight excess and hypertension. In line, ACEi exerts beneficial effects on renal hemodynamics in overweight and obesity [17]. There is data to suggest that DRI might be particularly effective in modulating renal RAAS [18]. However, the effect of DRI on renal hemodynamics and RAAS activity has not been tested so far in subjects with weight excess and hypertension. We therefore assessed the effect of DRI in maximal dose, with maximal dose ACEi as a positive control, on renal hemodynamics, twenty-four hour ambulant blood pressure, and on RAAS activity parameters in men with weight excess and hypertension.

## Material and Methods

### General trial information

This randomized, double-blind, cross-over clinical trial was performed between January 2011 and June 2012 at the Department of Medicine, Division of Nephrology, of the University Medical Center Groningen (UMCG), Groningen, The Netherlands (Trial protocol in [S1 Text](#)). Primary outcome measure of the trial were renal hemodynamics (glomerular filtration rate: GFR, effective renal plasma flow: ERPF, and filtration fraction: FF) and systemic blood pressure (systolic blood pressure: SBP, diastolic blood pressure: DBP, and mean arterial pressure: MAP) as

measured by twenty-four hour ambulatory blood pressure measurement (ABPM). Secondary outcome measures of the trial were RAAS activity (renin concentration and activity, aldosterone concentration, aldosterone/renin concentration ratio, and angiotensinogen concentration) and volume status (extracellular fluid volume: ECV). The trial was conducted according to the ethical principles of the Declaration of Helsinki and Good Clinical Practice (GCP), and was approved by the Independent Medical Ethics Committee of our University Medical Center (METc-number: 2010/228). The trial is registered at the Dutch trial register ([www.trialregister.nl](http://www.trialregister.nl); trial registration number: 2532). All participants provided written informed consent.

## Trial participants

We screened consecutive Caucasian men with weight excess and essential hypertension from our outpatient clinic for nephrology and hypertension, and from two local general practitioner clinics. Inclusion criteria were a BMI between  $>27$  and  $\leq 35$  Kg/m<sup>2</sup>, essential hypertension (WHO criteria; either treated with antihypertensive medication or untreated ambulant systolic and/or diastolic blood pressure  $\geq 140$  and/or  $\geq 90$  mmHg, respectively [19]), normal renal function (endogenous creatinine clearance  $\geq 90$  mL/min/1.73m<sup>2</sup>), and normo- or microalbuminuria (urinary albuminuria excretion  $< 300$  mg/day). For safety reasons we excluded subjects with off-treatment systolic and diastolic blood pressure of  $\geq 180$  and  $\geq 110$  mmHg, respectively, and subjects with a history of cardiovascular disease (myocardial infarction, angina pectoris, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, stroke, heart failure (stage I-IV of the New York Heart Association classification). Other main exclusion criteria were: diabetes mellitus, active malignancy, any medication and/or surgical or medical condition that might alter absorption, distribution, metabolism, or excretion of medication, history of hypersensitivity or contraindication to trial medication or radio-labeled tracers, history of angioedema, autonomic dysfunction, participation in any other clinical investigation within three months prior to start of the trial, blood or plasma donation within 3 months prior to initial dosing, and history of either drugs or alcohol abuse.

## Trial protocol

Subjects that were treated with antihypertensive medication prior to start of the trial were first enrolled in a 6-week wash-out period in which prior antihypertensive medication was stopped. NSAIDs were not allowed and discontinued at start of the wash-out period ( $n = 2$ ). Other non-trial drugs were kept stable during the trial. Consecutively, subjects were randomly assigned (1:1) to either a 6-week treatment period with angiotensin converting enzyme-inhibition (ACEi; ramipril 10 mg/day) and aliskiren-placebo or direct renin-blockade (DRI; aliskiren 300 mg/day) and ramipril-placebo, according to the double-dummy principle, in a cross-over fashion. An independent pharmacist randomized treatment sequences using a computer. The randomization code remained secret during the entire study and all patients, investigators, and health care providers were blinded, except for the pharmacist. Dose of DRI and ACEi were chosen on basis of their maximal recommended dose according to European Medicines Agency ([www.ema.europa.eu](http://www.ema.europa.eu)). After completion of the first treatment period, subjects enrolled in an 8-week wash-out period after which the second treatment period started.

Subjects visited our outpatient clinic for nephrology and hypertension at baseline, and after completion of the wash-out period and the 2 treatment periods for clinical assessment (body weight, and adverse events), measurement of renal hemodynamics (GFR, ERPF, and FF), monitoring of 24-hour ambulant and office blood pressure (SBP, DBP, and MAP), volume status (ECV), and for blood and 24-hour urine sampling for measurement of RAAS parameters (renin concentration and activity, aldosterone concentration, aldosterone/renin concentration

ratio, and angiotensinogen concentration), and routine hematology and biochemistry variables. Subjects were instructed to take trial medication once daily, in the morning, except when renal hemodynamic measurements were performed. Furthermore, subjects were instructed to adhere to a regular protein and sodium diet (being 1.1 g/Kg body weight/day and 200 mmol/day, respectively). No structured follow-up of subjects after trial completion was performed.

## Trial measurements and calculations

**Renal hemodynamics.** Constant infusion of radio-labeled tracers,  $^{125}\text{I}$ -iothalamate, and  $^{131}\text{I}$ -hippurate, was used to measure GFR and ERPF, respectively, with subjects being in a quiet room, in a semi-supine position. After drawing a blank blood sample, a priming solution containing 0.04 mL/Kg body weight of the infusion solution (0.04 MBq of  $^{125}\text{I}$ -iothalamate and 0.03 MBq of  $^{131}\text{I}$ -hippurate) plus an extra bolus of 0.06 MBq of  $^{125}\text{I}$ -iothalamate was given at 08:00 hours, followed by infusion at a rate of 12 mL/hour. In order to attain stable plasma concentrations of both tracers, a 2-hour stabilization period followed, after which baseline measurement started at 10:00 hours. The clearances were calculated as  $(U \times V)/P$  and  $(I \times V)/P$ , respectively.  $U \times V$  represents the urinary excretion of the tracer,  $I \times V$  represents the infusion rate of the tracer, and  $P$  represents the tracer value in plasma at the end of each clearance period. This method corrects for incomplete bladder emptying and dead space, by multiplying urinary clearance of  $^{125}\text{I}$ -iothalamate with the ratio of the plasma and urinary clearance of  $^{131}\text{I}$ -hippurate [20,21]. FF was calculated by dividing GFR by ERPF, and expressed as percentage. Renal vascular resistance (RVR) was calculated as the ratio of MAP (calculated with blood pressures measured during renal hemodynamic measurements as described further on), and renal blood flow, the latter being ERPF multiplied by 1 minus hematocrit. ECV was calculated using the distribution volume of  $^{125}\text{I}$ -iothalamate, as described previously [22].

To comply with common practice in literature, we indexed renal hemodynamic parameters, except FF, for body surface area (BSA). However, as this can induce bias when analyzing renal hemodynamics in overweight and obese subjects, we additionally repeated analyses for crude (mL/min) values of GFR, ERPF and RVR.

**Systemic hemodynamics.** Twenty-four hour ambulant blood pressure measurements (Spacelabs Medical<sup>®</sup>, Inc. Issaquah, WA, USA) were performed one day prior to the measurement of renal hemodynamics. At baseline, blood pressure was measured at both arms to check for presence of a clinical significant difference in blood pressure (present in none of the subjects). We measured upper-arm circumference at baseline to custom-fit cuff size, and subjects were instructed to place their arm in a resting position during blood pressure measurement. Blood pressure cuffs were applied by either a trained technician or by A.J.K. Blood pressure was measured every 30 minutes during both day- and night time. A measurement was noted as unsuccessful when number of recordings was less than 80% (1 patient at end of the DRI treatment period).

In addition, blood pressure was measured after completion of the 2-hour stabilization period during renal hemodynamic measurement, at 1-minute intervals by an semi-automatic device (Dinamap<sup>®</sup>, G.E. Medical Systems, Milwaukee, WI, USA), with subjects being in a quiet room, in a semi-supine position, and in a fasting condition. We used the mean of the single last 4 readings (last reading was omitted as subjects may react to the nurses entering the room). We expressed blood pressure as systolic, diastolic and mean arterial pressure, the last being calculated as diastolic pressure plus one third of pulse pressure.

**RAAS parameters.** Fasting blood samples were obtained at start of renal hemodynamic measurement, after a minimum semi-supine rest of 15 minutes. Twenty-four hour urine was collected at the day prior to the hospital visit. Blood samples for measurement of RAAS activity

parameters were immediately put on ice, centrifuged at 3000 RPM for 10 min at 4°C, and subsequently frozen on liquid nitrogen and stored at -80°C until analysis. Plasma renin activity was measured by determining angiotensin I generation at 37°C in the presence of angiotensinase inhibitors. Detection limit of this assay was 0.03 pmol angiotensin I /mL/hr, and the coefficient of variance (CV) was 11%. Plasma and urinary renin concentration were measured with an immunoradiometric assay (Renin III; Cisbio, Gif-sur-Yvette, France), with a detection limit of 1 pg/mL, and a coefficient of variance (CV) of 7%. Plasma and urinary aldosterone were measured with a radioimmunoassay (Coat-a-Count, Diagnostics Product Corporation, Siemens, LA, CA, USA). This assay has a detection limit of 11 pg/mL, and a CV of 8%. Plasma angiotensinogen was measured as the maximum quantity of angiotensin I that was generated during incubation with excess recombinant renin. The detection limit of this assay was 0.50 pmol/mL, and the CV was 10%. We expressed plasma angiotensinogen as pg/mL (multiplying by its molecular weight of 65 kDa). Urinary angiotensinogen was measured with a commercial angiotensinogen ELISA (IBL International, Hamburg, Germany), with a detection limit of 0.01 ng/mL, and a CV of 5%. Urinary measurements of RAAS parameters were performed in 24-hour urine samples and expressed as excretion rates per 24-hour. Aldosterone/renin concentration ratio was calculated by dividing aldosterone concentration by renin concentration. Urine/plasma concentration ratios of renin, aldosterone and angiotensinogen were calculated by dividing urinary concentration by plasma concentration, and were multiplied by 100%.

**Other measurements and calculations.** Routine hematology and biochemistry variables were measured within 2 hours after blood and urine sampling. Proteinuria and albuminuria were measured with a turbidimetric assay using benzethonium chloride (Modular, Roche Diagnostics, Mannheim, Germany). Values of urinary protein concentration were below detection limit (0.1 g/L) in 4, 3 and 4 subjects at baseline, DRI, and ACEi, respectively, and was set at 0.05 g/L in order to calculate urinary excretion rate. Urinary albuminuria concentration was below detection limit (1 mg/L) in one subject during ACEi, and was set at 0.5 mg/L. Blood electrolytes, lipids, glucose, and urinary electrolytes were measured using an automated multi-analyser (Modular, Roche Diagnostics, Mannheim, Germany). Creatinine clearance was calculated from creatinine concentration in plasma and 24-hour urine sample. Body mass index (BMI), as a measure of overall obesity, was calculated by dividing body weight by height squared ( $\text{kg}/\text{m}^2$ ). Obesity was defined as  $\text{BMI} > 30 \text{ kg}/\text{m}^2$ . Body surface area (BSA) was calculated according to the DuBois-DuBois formula [23]. Waist and hip circumference were measured on bare skin, at the natural indentation between the 10<sup>th</sup> rib and iliac crest and at the region of the trochanter major, respectively. Waist circumference was measured after an overnight fast and at end of normal expiration to avoid influence of stomach content and respiration phase on measurements. Waist-to-hip ratio (WHR) was calculated as waist circumference divided by hip circumference.

## Statistical analysis

We expected subjects to present with a mean unindexed ERPF of 444 mL/min at baseline. As ample size calculation (two-sided T-test) was performed on basis of a hypothesized increase in ERPF of 47 mL/min with DRI and 29 mL/min with ACEi [15,24], with a standard deviation in ERPF response of 17 mL/min. In order to give the trial 90% power to detect a statistically significant increase in ERPF during both ACEi and DRI ( $\alpha = 0.05$ ) we calculated that a total of fourteen subjects had to complete the cross-over design sequence. We aimed to randomize 16 subjects at start of the trial to anticipate on a dropout rate of 10%.

Analyses were performed after database was locked. Paired T-tests were used to determine treatment response. Non-normally distributed variables were  $\log_{10}$ -transformed before analysis.

In addition, we analysed data by linear mixed model analysis, including a Bonferroni correction, with renal and systemic hemodynamics and RAAS-parameters as dependent variables, subjects as a random factor, and treatment (ACEi or DRI) and sequence (start with either ACEi or DRI) as well as their interaction (treatment x sequence) as fixed factors, to account for repeated measurements and to check for presence of any potential carry-over effects of treatment. As this analysis did not essentially change results we only present paired T-tests. Renal hemodynamic and blood pressure measurements were essentially similar for baseline and wash-out period, and therefore only baseline data are shown. Data are given as mean with standard error of mean (SEM) when normally distributed, and otherwise as geometric mean with 95% confidence interval (95% CI). Data was analyzed using SPSS version 20.0 (SPSS Inc., Chicago, IL) and GraphPad Prism version 5 (GraphPad Software Inc., San Diego, CA). Statistical significance was assumed at the 5% level of probability.

## Results


### Trial population

We invited 64 overweight/obese hypertensive male subjects for an information visit at the outpatient clinic of which 17 subjects responded and were subsequently found eligible for participation. During the run-in period, 1 patient was excluded because of asymptomatic subclinical hypothyroidism with high anti-thyroid peroxidase auto-antibodies for which thyroid hormone substitution was indicated. The remaining 16 subjects were randomized. After baseline measurement, 1 subject refused further participation due to lack of motivation and was therefore excluded. A total of 15 subjects completed the trial and were included in analyses (Fig 1).

Subject characteristics are shown in Table 1. By default, subjects were hypertensive and overtly overweight, with 47% being obese (defined as BMI > 30 Kg/m<sup>2</sup>). Fasting plasma glucose, HbA1C, and cholesterol levels were all within normal limits. Before trial enrollment, 10 (67%) subjects used 1 [0–2] antihypertensive medication, being either ACEi (n = 7), ARB (n = 3), diuretics (n = 7), or calcium channel blockers (n = 1). No statistical differences in subject characteristics were noted when stratified for treatment of initiation (S1 Table). Compliance to ACEi and DRI capsules during both trial periods, as assessed by pill counts, was > 85% in all but one subject that had a compliance of 76% during the ACEi treatment.

### Renal hemodynamics

BSA-indexed renal hemodynamic parameters at baseline and after six week treatment with DRI and ACEi are shown in Fig 2. Mean (SEM) GFR/BSA at baseline was 101 (5) mL/min/1.73m<sup>2</sup> and remained essentially unaffected by DRI (102 (5) mL/min/1.73m<sup>2</sup>, P = 0.9) and by ACEi (104 (4) mL/min/1.73m<sup>2</sup>, P = 0.1). ERPF/BSA was significantly increased in response to DRI (320 (14) mL/min/1.73m<sup>2</sup>, P = 0.012) and ACEi (317 (15) mL/min/1.73m<sup>2</sup>, P = 0.045) compared to baseline (301 (14) mL/min/1.73m<sup>2</sup>). Both DRI (0.45 (0.03), P = 0.004) and ACEi (0.47 (0.03), P = 0.024) reduced RVR/BSA compared to baseline (0.53 (0.05)), although FF was only significantly reduced in response to DRI treatment (DRI: 32 (0.7)%, P = 0.044 and ACEi: 33 (0.7)%, P = 0.4, respectively) compared to baseline (34 (0.8)%). Essentially similar results were found when we repeated analyses with crude GFR, ERPF and RVR (Table 2; see S1 Table for data stratified by treatment of initiation). Although there was a tendency of stronger effects on renal hemodynamics with DRI, the difference in response of ERPF, RVR and FF between DRI and ACEi was not significant. Furthermore, linear mixed model analysis did not essentially change results.



**Fig 1. Flow chart of inclusion.**

doi:10.1371/journal.pone.0169258.g001

### Systemic hemodynamics

Fig 3 shows data on twenty-four hour ambulant blood pressure measurements at baseline and after six week treatment with DRI and ACEi. Mean (SEM) baseline systolic blood pressure (147 (3) mmHg) was significantly reduced in response to DRI (137 (4) mmHg,  $P = 0.027$ ) and nominally reduced in response to ACEi (140 (4) mmHg,  $P = 0.1$ ). Baseline diastolic blood pressure (91 (2) mmHg) was significantly reduced by both DRI (83 (2) mmHg,  $P = 0.004$ ) and ACEi (85 (2) mmHg,  $P = 0.019$ ). Consequently, both DRI (101 (2) mmHg,  $P = 0.008$ ) and ACEi (103 (3) mmHg,  $P = 0.037$ ) reduced MAP compared to baseline (109 (2) mmHg). Results obtained by twenty-four hour ambulant blood pressure measurements were confirmed by office blood pressure measurement at time of renal hemodynamic measurements using a semi automatic device (Table 2). There was no significant difference in blood pressures response between DRI and ACEi. Essential similar results were found with linear mixed model analysis.

### RAAS activity

Fig 4 shows data on RAAS parameters at baseline and after six week treatment with DRI and ACEi. All subjects had a pronounced rise and reduction in plasma renin concentration and aldosterone/renin ratio, respectively, confirming good compliance to trial medication. Geometric mean (95% CI) of plasma renin activity at baseline (0.9 [0.6–1.3] pmol Ang I /mL/hr)



**Table 1. Subject characteristics (n = 15).**


Age (years)	58 (3)
Male gender, n (%)	15 (100%)
BMI (Kg/m <sup>2</sup> )	30 (1)
Obesity, n (%)	7 (47%)
Office SBP (mmHg)	149 (5)
Office DBP (mmHg)	93 (3)
AHM prior to inclusion, n [range]	1 [0–2]
Waist circumference (cm)	108 (2)
Hip circumference (cm)	103 (2)
WHR	1.06 (0.02)
HbA1C (%)	5.8 (0.16)
Fasting plasma glucose (mmol/L)	5.9 (0.3)
Total cholesterol (mmol/L)	4.9 (0.2)
LDL cholesterol (mmol/L)	3.2 (0.2)
HDL cholesterol (mmol/L)	1.2 (0.1)

Data are shown as mean (SEM) or as geometric mean (95% CI) when indicated. Office blood pressure was measured with semi automatic blood pressure device (Dinamap®).

Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; AHM: antihypertensive medication; WHR: waist-to-hip ratio; LDL: low density lipoprotein; HDL: high density lipoprotein.

doi:10.1371/journal.pone.0169258.t001

was significantly reduced in response to DRI (0.2 [0.1–0.3] pmol Ang I /mL/hr,  $P < 0.001$ ), and significantly increased in response to ACEi (2.1 [1.4–3.1] pmol Ang I /mL/hr,  $P < 0.001$ ). Plasma renin concentration and urinary renin excretion at baseline (7.0 [4.7–10.4] pg/mL and 3.4 [2.3–5.0 ng/day], resp.) were significantly increased by DRI (35.4 [20.3–61.9] pg/mL and 7.5 [4.8–11.9] ng/day, resp.; both  $P < 0.001$  vs. baseline) and to a lesser extent by ACEi (19.2 [12.0–30.7] pg/mL and 4.8 [3.2–7.1] ng/day, resp.; both  $P < 0.001$  vs. baseline). Urinary excretion of aldosterone at baseline (5672 [5672–10290] ng/day) was significantly reduced by DRI (4969 [3475–7106] ng/day,  $P = 0.014$ ) and ACEi (4987 [3084–8062] ng/day,  $P = 0.036$ ), without affecting plasma aldosterone levels (98 [73–130] pg/mL, 95 [64–142] pg/mL, and 122 [84–176] pg/mL for baseline, DRI and ACEi, resp.;  $P > 0.05$  for both DRI and ACEi). Consequently, aldosterone/renin concentration ratio in both plasma and urine at baseline (14.0 [8.9–22.0] and 2248 [1444–3499], resp.) were significantly reduced by DRI (2.7 [1.6–4.5],  $P < 0.001$ ) and 660 [339–1288],  $P = 0.012$ ) and to a lesser extent by ACEi (6.4 [4.0–10.2],  $P < 0.001$  and 1046 [533–2054], resp.  $P < 0.001$ ). Plasma angiotensinogen at baseline (97295 [86438–109515] ng/mL) was not affected by DRI (91688 [75576–111235] ng/mL,  $P = 0.6$ ), but significantly reduced by ACEi (86488 [77523–96490] ng/mL,  $P = 0.023$ ). In contrast, urinary angiotensinogen at baseline (4067 [1448–11425] ng/day) was significantly reduced by DRI (1325 [531–3304] ng/day,  $P = 0.009$ ) and not by ACEi (2378 [907–6237] ng/day,  $P = 0.1$ ). Data on urine/plasma concentration ratios of renin, aldosterone and angiotensinogen are shown in Fig 5. The urine/plasma concentration ratio of renin and angiotensinogen at baseline (24 [12–47]% and 0.0020 [0.0008–0.0051]%, resp.) were significantly reduced in response to DRI (10 [4–27]%,  $P = 0.023$  and 0.0007 [0.0003–0.0017]%,  $P = 0.009$ , resp.). The urine/plasma concentration ratio of aldosterone was neither affected by DRI nor by ACEi. DRI had overall a stronger effect on RAAS activity parameters, which reached statistical significance for plasma and urinary renin concentration ( $P = 0.009$  and  $P = 0.001$  compared to ACEi, resp.) and plasma and urinary aldosterone/renin concentration ratio ( $P = 0.001$  and  $P = 0.002$  compared to ACEi, resp.).



**Fig 2. Renal hemodynamic parameters at baseline and after 6-week treatment with ACEi and DRI.** Renal hemodynamic data indexed for BSA. Data shown as mean (SEM). Abbreviations: BSA: body surface area; GFR: glomerular filtration rate; ERPF: effective renal plasma flow; FF: filtration fraction.

doi:10.1371/journal.pone.0169258.g002

### Additional biochemical parameters and side effects

Table 3 shows data on albuminuria, volume status, and plasma and urine measurements at baseline and after treatment with DRI and ACEi. Urinary albumin excretion rate was in the normal range at baseline (20 [9–42] mg/day) and showed a significant reduction by DRI (12

**Table 2. Renal hemodynamics and systemic blood pressure measurements at baseline and after treatment with ACEi and DRI.**

	Baseline	ACEi	DRI
<b>Crude renal hemodynamic data</b>			
GFR (mL/min)	130 (7)	133 (6)	131 (7)
ERPF (mL/min)	386 (19)	406 (20)*	411 (18)**
RVR (mmHg/mL/min)	0.67 (0.05)	0.60 (0.04)*	0.58 (0.04)**
FF (%)	34 (0.8)	33 (0.7)	32 (0.07)*
<b>Semi-automatic blood pressure data (DINAMAP®)</b>			
SBP (mmHg)	149 (5)	142 (4)**	136 (3)**
DBP (mmHg)	93 (3)	87 (3)	85 (3)*
MAP (mmHg)	112 (4)	106 (3)*	102 (3)**

Data are shown as mean (SEM). Abbreviations: BSA: body surface area; GFR: glomerular filtration rate; ERPF: effective renal plasma flow; FF: filtration fraction, RVR: renal vascular resistance; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure.

\* P<0.05 vs. baseline


\*\* P<0.01 vs. baseline.

doi:10.1371/journal.pone.0169258.t002

[5–28] mg/day, P = 0.030), however not by ACEi (16 [7–35] mg/day, P = 0.3). Urinary protein excretion rate was in the low-normal range at baseline (0.1 [0.1–0.1] g/day), however, unresponsive to either DRI or ACEi.


Mean urinary sodium excretion at baseline was 205 (21) mmol/day and remained stable throughout the trial. In line with this, ECV, body weight, and urinary volume remained also unaffected by either DRI or ACEi. Serum potassium at baseline (3.9 (0.1) mmol/L) showed a small but significant increase by DRI (4.0 (0.1) mmol/L, P = 0.043), but not by ACEi (4.0 (0.1) mmol/L, P = 0.5). None of the subjects developed hyperkalemia (defined as K<sup>+</sup> >5.0 mmol/L). Urinary potassium excretion remained stable throughout the trial.

One patient complained of dry cough and symptomatic hypotension during treatment with DRI, which did not result in dosage reduction of trial medication and was resolved after completion of the trial period.



**Fig 3. Blood pressure measured by ABPM at baseline and after 6-week treatment with ACEi and DRI.** Individual data are shown as well as mean (SEM). ABPM measurement was unsuccessful in one patient during DRI treatment due to insufficient number of recordings (<80%). Abbreviations: SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure.

doi:10.1371/journal.pone.0169258.g003




**Fig 4. RAAS parameters in plasma (upper panel) and urine (lower panel) at baseline and after 6-week treatment with ACEi and DRI.** Data shown as geometric mean (95% CI).

doi:10.1371/journal.pone.0169258.g004

### Discussion

In men with weight excess and hypertension, DRI significantly increased ERPF, and reduced RVR and FF, along with a significant reduction in systemic blood pressure and albuminuria. ACEi, which served as a positive control, significantly increased ERPF and reduced RVR, with a nominal reduction in FF. RAAS activity was significantly reduced by both DRI and ACEi.



**Fig 5. Renal angiotensinogen handling at baseline and after 6-week treatment with ACEi and DRI.** Data shown as geometric mean (95% CI).

doi:10.1371/journal.pone.0169258.g005

**Table 3. Clinical parameters at baseline and after treatment with ACEi and DRI.**

	Baseline	ACEi	DRI
<b>Clinical parameters</b>			
Body weight (Kg)	101 (3)	100 (3)	100 (3)
ECV (L)	22.7 (1.1)	23.8 (1.3)	24.1 (1.0)
<b>Plasma and serum measurements</b>			
Hemoglobin (mmol/L)	9.5 (0.2)	9.5 (0.1)	9.4 (0.2)
Hematocrit (v/v)	0.45 (0.01)	0.45 (0.01)	0.44 (0.01)
Sodium (mmol/L)	141 (0.4)	141 (0.4)	140 (0.5)
Potassium (mmol/L)	3.9 (0.1)	3.9 (0.1)	4.0 (0.1)*
Urea (mmol/L)	6.1 (0.3)	5.9 (0.3)	5.7 (0.3)
Creatinine (μmol/L)	78 (3)	79 (3)	77 (3)
Creatinine clearance (mL/min)	141 (7)	147 (13)	140 (12)
<b>Urine measurements</b>			
Albuminuria (mg/day)	20 [9–42]	16 [7–35]	12 [5–28]*
Proteinuria (g/day)	0.1 [0.1–0.1]	0.1 [0.1–0.1]	0.1 [0.1–0.1]
Urinary volume (mL/day)	2106 (195)	2076 (161)	2178 (193)
Creatinine excretion (mmol/day)	15.9 (0.7)	16.9 (1.0)	16.1 (0.6)
Sodium excretion (mmol/day)	205 (21)	248 (16)	223 (16)

Data are shown as mean (SEM) or as geometric mean (95% CI) when indicated.

\* P<0.05 vs. baseline.

\*\* P<0.01 vs. baseline.

doi:10.1371/journal.pone.0169258.t003

This trial demonstrated that DRI is an effective treatment for obese hypertensive men, in line with the known beneficial effect of ACEi, with a potentially favorable renal profile.

The renal hemodynamic response to DRI, as found in this trial, is in line with previous studies in essential hypertensives during liberal sodium intake [18,25–29]. Studies that specifically investigated aliskiren also found a renal vasodilator response [24,30]. Of note, these studies included normal weight subjects only, whereas overweight and obese subjects could theoretically benefit most from direct renin blockade. Our trial therefore adds to the current literature as it is the first to demonstrate an effect of DRI on renal hemodynamics in subjects with weight excess and hypertension.

We found a significant reduction in automatic twenty-four hour ambulatory and semi-automatic office blood pressure. In contrast to renal hemodynamics, the effect of DRI on systemic hemodynamics has been relatively well characterized in obese subjects, with studies reporting of an unequivocal reduction in blood pressure [31–37], that sustained over a minimal period of 6 to 12 months [33,36,37].

Furthermore, we found a pronounced reduction in RAAS activity in response to DRI, as reflected by a significant reduction in plasma renin activity and a significant increase in both plasma renin concentration and urinary renin excretion. Moreover, we found a significant reduction in plasma and urinary aldosterone/renin concentration ratio in response to DRI, accompanied by a significant reduction in urine/plasma concentration ratio of renin. The rise in renin excretion combined with the reduction in the urine/plasma concentration ratio of renin raises the question to what degree these data indicate activation or suppression of the renal RAAS. Here it is important to realize that the majority of urinary renin is plasma-derived. This is evidenced by the up to 40-fold higher urinary renin levels in patients with Dent’s disease or Lowe syndrome, in whom tubular reabsorption of filtered renin (by megalin) is disturbed [38]. On this basis, urinary renin levels should be corrected for plasma renin levels.

Yet, there is also evidence for renin production in the collecting duct. Surprisingly, here angiotensin II stimulates local renin release, as opposed to its inhibitory effects on renin release in the juxtaglomerular apparatus [39,40]. Therefore, given the drop in Angiotensin II after DRI, and assuming that some urinary renin originates from the collecting duct, a decrease in the urine/plasma concentration ratio of renin would be expected. Since this is exactly what occurred, it appears that DRI attenuates RAAS activation in the kidney, i.e., does not result in selective upregulation of collecting duct renin. Clearly however, alternative explanations, like alterations in tubular megalin expression, should be considered as well.

Another question that needs to be addressed is to what degree the elevated renin levels during DRI would exert angiotensin II-independent effects, via binding to the so-called (pro) renin receptor [41]. Indeed, *in vitro*, renin inhibitors do not interfere with such binding [42], although obviously they do block renin activity. Renin/prorenin binding to this receptor results in the activation of multiple second messenger pathways [41]. However, the binding affinity of this receptor for renin and its precursor prorenin was found to be in the nanomolar range, while their *in-vivo* levels are many orders below this range, even during DRI treatment [43, 44]. On this basis, combined with the fact that the (pro)renin receptor is now additionally known to be an accessory subunit of vacuolar H<sup>+</sup>-ATPase, displaying multiple effects that are entirely unrelated to renin and/or prorenin, e.g., with regard to cardiomyocyte autophagy [45], polyuria and renal acid-base regulation [46], and LDL metabolism [47], this idea is now being abandoned [48].

Aldosterone levels were significantly reduced by DRI in urine, however, not in plasma, despite the fact that urinary aldosterone is plasma-derived. This is most likely related to much lower concentrations in plasma compared to urine, which limits the ability to detect statistical differences. Our observations are in line with studies stating that plasma aldosterone is a less sensitive marker of RAAS activity [49]. We found a reduction in urinary angiotensinogen which was paralleled by a reduction in urine/plasma ratio of angiotensinogen. Urinary angiotensinogen might be both kidney- and plasma-derived. In case of the former, the reduction in urinary angiotensinogen would be suggestive of a suppression of renal RAAS activity [50]. In case of the latter, angiotensinogen would be a marker for permeability of the glomerular filtration barrier [49, 51]. Our data, showing a similar response of urinary angiotensinogen and albuminuria to DRI, are consistent with the second concept. Moreover, 2 seminal papers by Matsusaka et al. [52, 53], making use of kidney-specific angiotensinogen knockout mice, revealed that, both under normal and pathological conditions, renal angiotensin II production depends entirely on plasma-derived (i.e., hepatic) angiotensinogen. Therefore, the function of locally produced angiotensinogen in the kidney, if any, remains controversial.

We believe that our trial adds to the current understanding of the RAAS in response to DRI by its extensive characterization of multiple RAAS parameters simultaneously, in both plasma and urine, thereby rendering an effect of DRI not only on systemic, but also on intrarenal RAAS activity plausible [54,55].

DRI might have a stronger effect on renal hemodynamics than other RAAS blocking agents [24,55], with possibly a stronger effect on systemic hemodynamics as well [34–36, 54]. One explanation for this could be that RAAS activity is more efficiently blocked by DRI, as it intervenes in the RAAS at its point of activation [56]. Another explanation might be its long pharmacokinetic half-life (up to 36 hours [56] and/or its ability to penetrate adipose, skeletal and renal tissue—with renal accumulation of aliskiren up to two weeks after drug withdrawal—thereby affecting RAAS activity at a tissue level [57, 58]. In our trial, we found only a trend towards stronger effect of DRI, although it should be noted that our trial was not designed nor powered to investigate a quantitative difference in efficacy between DRI and ACEi. A quantitative difference in efficacy can only be adequately investigated in a dose-response study.

Several limitations of this trial should be considered. First of all, we studied the effects of DRI during liberal sodium intake, while the effect of RAAS blockade is known to be potentiated by even mild sodium restriction, or diuretics [59]. The efficacy in a setting of clinical treatment of hypertension might thus be underestimated. Second, as the number of studied subjects was relatively small, we optimized the signal-to-noise ratio by solely including men, as physiological variation in circulating estrogens levels in women is known to influence renal hemodynamic measurements and RAAS activity [60,61]. Whereas the cross-over design of the trial, with every subject being its own control, provided us adequate power to detect effects of DRI, however, this set-up limits the generalizability of the results. Third, we did not include a control group to compare the renal response to DRI between healthy and obese subjects.

In conclusion, we found a favorable renal and systemic hemodynamic response to DRI, accompanied by a reduction in RAAS activity and albuminuria, in men with weight excess and hypertension.

## Supporting Information

### **S1 CONSORT Checklist.**

(DOC)

### **S1 Text. Trial protocol.**

(PDF)

### **S1 Table. Subject characteristics stratified by treatment of initiation.**

(DOCX)

## Acknowledgments

We highly appreciated patients for their willingness to contribute to this trial. We thank Dir-kina Hesselting-Swaveling, Roelie Karsten-Bartelds, and Marian Vroom-Dallinga for performing renal hemodynamic measurements. We are very grateful for the skillful assistance of Annemarie Zantman at the outpatient clinic for nephrology and hypertension. We also thank Tsjitske Toering, Laura de Vries, and Arie van Roon for kindly providing twenty-four hour ambulant blood pressure measurement devices.

## Author Contributions

**Conceptualization:** GJN GDL AJK.

**Data curation:** AJK.

**Formal analysis:** AJK.

**Funding acquisition:** GJN.

**Investigation:** AJK.

**Methodology:** GJN GDL AJK.

**Project administration:** AJK.

**Resources:** GDL GAL JHvEA MAK HJLH AHJD IvdB-G.

**Supervision:** GJN GDL HJLH AHJD.

**Visualization:** AJK.

**Writing – original draft:** AJK.

**Writing – review & editing:** GJN GDL HJHL HK LCR AHJD.

## References

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. *JAMA* 2006; 295:1549–1555. doi: [10.1001/jama.295.13.1549](https://doi.org/10.1001/jama.295.13.1549) PMID: [16595758](https://pubmed.ncbi.nlm.nih.gov/16595758/)
2. International Obesity Task Force EU Platform Briefing Paper; prepared in collaboration with the European Association for the Study of Obesity; March 15 2005 Brussels.
3. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. *Arch Intern Med* 2002; 162(16):1867–1872. PMID: [12196085](https://pubmed.ncbi.nlm.nih.gov/12196085/)
4. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. *N Engl J Med* 1999; 341:1097–1105. doi: [10.1056/NEJM199910073411501](https://doi.org/10.1056/NEJM199910073411501) PMID: [10511607](https://pubmed.ncbi.nlm.nih.gov/10511607/)
5. Ejerblad E, Forde CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk for chronic renal failure. *J Am Soc Nephrol* 2006; 17(6):1695–1702. doi: [10.1681/ASN.2005060638](https://doi.org/10.1681/ASN.2005060638) PMID: [16641153](https://pubmed.ncbi.nlm.nih.gov/16641153/)
6. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. *N Engl J Med* 1996; 334:13–18. doi: [10.1056/NEJM199601043340103](https://doi.org/10.1056/NEJM199601043340103) PMID: [7494564](https://pubmed.ncbi.nlm.nih.gov/7494564/)
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; 360:1903–1913. PMID: [12493255](https://pubmed.ncbi.nlm.nih.gov/12493255/)
8. Ribstein J, du CG, Mimran A. Combined renal effects of overweight and hypertension. *Hypertension* 1995; 26:610–615. PMID: [7558220](https://pubmed.ncbi.nlm.nih.gov/7558220/)
9. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. *J Am Soc Nephrol* 2003; 14:469–477. PMID: [12538749](https://pubmed.ncbi.nlm.nih.gov/12538749/)
10. Messerli FH, Christie B, DeCarvalho JG, Aristimuno GG, Suarez DH, Dreslinski GR, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. *Arch Intern Med* 1981; 141:81–85. PMID: [7004372](https://pubmed.ncbi.nlm.nih.gov/7004372/)
11. Navis G, de Jong PE, Donker AJ, van der Hem GK, de Zeeuw D. Effects of enalaprilic acid on sodium excretion and renal hemodynamics in essential hypertension. *J Clin Hypertens* 1985; 1:228–238. PMID: [3012004](https://pubmed.ncbi.nlm.nih.gov/3012004/)
12. Kwakernaak AJ, Toering TJ, Navis G. Body mass index and body fat distribution as renal risk factors: a focus on the role of renal hemodynamics. *Nephrol Dial Transplant* (in press).
13. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. *Kidney Int* 1983; 23:647–655. PMID: [6336299](https://pubmed.ncbi.nlm.nih.gov/6336299/)
14. Bosma RJ, Kwakernaak AJ, van der Heide JJ, de Jong PE, Navis GJ. Body mass index and glomerular hyperfiltration in renal transplant recipients: cross-sectional analysis and long-term impact. *Am J Transplant* 2007; 7:645–652. doi: [10.1111/j.1600-6143.2006.01672.x](https://doi.org/10.1111/j.1600-6143.2006.01672.x) PMID: [17250561](https://pubmed.ncbi.nlm.nih.gov/17250561/)
15. Apperloo AJ, de Zeeuw D, de Jong PE. Discordant effects of enalapril and lisinopril on systemic and renal hemodynamics. *Clin Pharmacol Ther* 1994; 56:647–658. PMID: [7995007](https://pubmed.ncbi.nlm.nih.gov/7995007/)
16. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). *Lancet* 1997; 349:1857–1863. PMID: [9217756](https://pubmed.ncbi.nlm.nih.gov/9217756/)
17. Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. *Hypertension* 2005; 46:1316–1320. doi: [10.1161/01.HYP.0000190819.07663.da](https://doi.org/10.1161/01.HYP.0000190819.07663.da) PMID: [16286575](https://pubmed.ncbi.nlm.nih.gov/16286575/)
18. Fisher ND, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, et al. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. *Hypertension* 1994; 23:44–51. PMID: [8282330](https://pubmed.ncbi.nlm.nih.gov/8282330/)
19. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. *J Hypertens* 1999; 17:151–183. PMID: [10067786](https://pubmed.ncbi.nlm.nih.gov/10067786/)
20. Apperloo AJ, de Zeeuw D, Donker AJ, de Jong PE. Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran. *J Am Soc Nephrol* 1996; 7:567–572. PMID: [8724890](https://pubmed.ncbi.nlm.nih.gov/8724890/)



21. Donker AJ, van der Hem GK, Sluiter WJ, Beekhuis H. A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. *Neth J Med* 1977; 20:97–103. PMID: [882199](#)
22. Visser FW, Muntinga JH, Dierckx RA, Navis G. Feasibility and impact of the measurement of extracellular fluid volume simultaneous with GFR by <sup>125</sup>I-iothalamate. *Clin J Am Soc Nephrol* 2008; 3:1308–1315. doi: [10.2215/CJN.05501207](#) PMID: [18650405](#)
23. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. *Nutrition* 1989; 5:303–311. PMID: [2520314](#)
24. Fisher ND, Danser AHJ, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. *Circulation* 2008; 117:3199–3205. doi: [10.1161/CIRCULATIONAHA.108.767202](#) PMID: [18559696](#)
25. Fisher ND, Hollenberg N. Renal vascular responses to renin inhibition with zankiren in men. *Clin Pharmacol Ther* 1995; 57:342–348. doi: [10.1016/0009-9236\(95\)90160-4](#) PMID: [7697952](#)
26. van Paassen P, Navis GJ, de Jong PE, de Zeeuw D. Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. *Eur J Clin Invest* 1999; 29:1019–1026. PMID: [10583449](#)
27. van Paassen P, de Zeeuw D, de Jong PE, Navis G. Renin inhibition improves pressure natriuresis in essential hypertension. *J Am Soc Nephrol* 2000; 11:1813–1818. PMID: [11004211](#)
28. van Paasen P, de Zeeuw D, de Jong PE. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. *J Cardiovasc Pharmacol* 1995; 26:39–45. PMID: [7564363](#)
29. van Paassen P, de Zeeuw D, Navis G, de Jong PE. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. *Nephrol Dial Transplant* 2000; 15:637–643. PMID: [10809804](#)
30. Cherney DZ, Lai V, Scholey JW, Miller JA, Zinman B, Reich HN. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. *Diabetes Care* 2010; 33:361–365. doi: [10.2337/dc09-1303](#) PMID: [19889802](#)
31. Jordan J, Engeli S, Boye SW, Le BS, Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. *Hypertension* 2007; 49:1047–1055. doi: [10.1161/HYPERTENSIONAHA.106.084301](#) PMID: [17353513](#)
32. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. *Am J Hypertens* 2007; 20:11–20. doi: [10.1016/j.amjhyper.2006.06.003](#) PMID: [17198906](#)
33. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. *J Hypertens* 2009; 27:1493–1501. doi: [10.1097/HJH.0b013e32832be593](#) PMID: [19444142](#)
34. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. *Circulation* 2005; 111:1012–1018. doi: [10.1161/01.CIR.0000156466.02908.ED](#) PMID: [15723979](#)
35. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. *Hypertension* 2003; 42:1137–1143. doi: [10.1161/01.HYP.0000101688.17370.87](#) PMID: [14597641](#)
36. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. *J Hypertens* 2008; 26:589–599. doi: [10.1097/HJH.0b013e3282f3ad9a](#) PMID: [18300872](#)
37. Sica D, Gradman AH, Lederballe O, Kolloch RE, Zhang J, Keefe DL. Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase. *Clin Drug Investig* 2011; 31:825–837. doi: [10.2165/11590280-000000000-00000](#) PMID: [22035463](#)
38. Roksnoer LC, Heijnen BF, Nakano D, Peti-Peterdi J, Walsh SB, Garrelds IM, et al. On the Origin of Urinary Renin: A Translational Approach. *Hypertension* 2016; 67:927–933. doi: [10.1161/HYPERTENSIONAHA.115.07012](#) PMID: [26928805](#)
39. Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H, Ozawa Y, Hering-Smith KS, Hamm LL, et al. Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. *Hypertension* 2004; 44:223–229. doi: [10.1161/01.HYP.0000135678.20725.54](#) PMID: [15226276](#)

40. Prieto-Carrasquero MC, Kobori H, Ozawa Y, Gutierrez A, Seth D, Navar LG. AT1 receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. *Am J Physiol Renal Physiol* 2005; 289:F632–F637. doi: [10.1152/ajprenal.00462.2004](https://doi.org/10.1152/ajprenal.00462.2004) PMID: [15870381](https://pubmed.ncbi.nlm.nih.gov/15870381/)
41. Nguyen G, Muller DN. The biology of the (pro)renin receptor. *J Am Soc Nephrol* 2010; 21:18–23. doi: [10.1681/ASN.2009030300](https://doi.org/10.1681/ASN.2009030300) PMID: [19917780](https://pubmed.ncbi.nlm.nih.gov/19917780/)
42. Batenburg WW, de Bruin RJ, van Gool JM, Müller DN, Bader M, Nguyen G, et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 2008; 28:1151–1157. doi: [10.1161/ATVBAHA.108.164210](https://doi.org/10.1161/ATVBAHA.108.164210) PMID: [18388329](https://pubmed.ncbi.nlm.nih.gov/18388329/)
43. Batenburg WW, Lu X, Leijten F, Maschke U, Müller DN, Danser AH. Renin- and prorenin-induced effects in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually occur? *Hypertension* 2011; 58:1111–1119. doi: [10.1161/HYPERTENSIONAHA.111.180737](https://doi.org/10.1161/HYPERTENSIONAHA.111.180737) PMID: [22025376](https://pubmed.ncbi.nlm.nih.gov/22025376/)
44. Batenburg WW, Danser AH. (Pro)renin and its receptors: pathophysiological implications. *Clin Sci* 2012; 123:121–133. doi: [10.1042/CS20120042](https://doi.org/10.1042/CS20120042) PMID: [22494159](https://pubmed.ncbi.nlm.nih.gov/22494159/)
45. Kinouchi K, Ichihara A, Sano M, Sun-Wada GH, Wada Y, Kurauchi-Mito A, et al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H<sup>+</sup>-ATPase assembly in murine cardiomyocytes. *Circ Res*. 2010; 107:30–34. doi: [10.1161/CIRCRESAHA.110.224667](https://doi.org/10.1161/CIRCRESAHA.110.224667) PMID: [20570919](https://pubmed.ncbi.nlm.nih.gov/20570919/)
46. Trepiccione F, Gerber SD, Grahammer F, López-Cayuqueo KI, Baudrie V, Păunescu TG, et al. Renal Atp6ap2/(Pro)renin Receptor Is Required for Normal Vacuolar H<sup>+</sup>-ATPase Function but Not for the Renin-Angiotensin System. *J Am Soc Nephrol* 2016 [Epub ahead of print].
47. Lu X, Meima ME, Nelson JK, Sorrentino V, Loregger A, Scheij S, et al. Low-Density Lipoprotein Metabolism. *Circ Res* 2016; 118:222–229. doi: [10.1161/CIRCRESAHA.115.306799](https://doi.org/10.1161/CIRCRESAHA.115.306799) PMID: [26582775](https://pubmed.ncbi.nlm.nih.gov/26582775/)
48. Danser AH. The Role of the (Pro)renin Receptor in Hypertensive Disease. *Am J Hypertens* 2015; 28:1187–1196. doi: [10.1093/ajh/hpv045](https://doi.org/10.1093/ajh/hpv045) PMID: [25890829](https://pubmed.ncbi.nlm.nih.gov/25890829/)
49. van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, et al. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney. *J Hypertens* 2011; 29:2147–2155. doi: [10.1097/HJH.0b013e32834bbcbf](https://doi.org/10.1097/HJH.0b013e32834bbcbf) PMID: [21941204](https://pubmed.ncbi.nlm.nih.gov/21941204/)
50. Kobori H, Navar LG. Urinary Angiotensinogen as a Novel Biomarker of Intrarenal Renin-Angiotensin System in Chronic Kidney Disease. *Int Rev Thromb* 2011; 6:108–116. PMID: [22022346](https://pubmed.ncbi.nlm.nih.gov/22022346/)
51. Persson F, Lu X, Rossing P, Garrelds IM, Danser AH, Parving HH. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? *J Hypertens* 2013; 31:1646–1652. doi: [10.1097/HJH.0b013e328362217c](https://doi.org/10.1097/HJH.0b013e328362217c) PMID: [23743807](https://pubmed.ncbi.nlm.nih.gov/23743807/)
52. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, et al. Liver angiotensinogen is the primary source of renal angiotensin II. *J Am Soc Nephrol* 2012; 23:1181–1189. doi: [10.1681/ASN.2011121159](https://doi.org/10.1681/ASN.2011121159) PMID: [22518004](https://pubmed.ncbi.nlm.nih.gov/22518004/)
53. Ortiz-Melo DI, Spurney RF. Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver-derived angiotensinogen. *Kidney Int* 2014; 85:1009–1011. doi: [10.1038/ki.2013.440](https://doi.org/10.1038/ki.2013.440) PMID: [24786873](https://pubmed.ncbi.nlm.nih.gov/24786873/)
54. Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. *J Renin Angiotensin Aldosterone Syst* 2007; 8:190–198. doi: [10.3317/jraas.2007.028](https://doi.org/10.3317/jraas.2007.028) PMID: [18205098](https://pubmed.ncbi.nlm.nih.gov/18205098/)
55. Cordero P, Fisher ND, Moore TJ, Gleason R, Williams GH, Hollenberg NK. Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans. *Hypertension* 1991; 17:510–516. PMID: [2013477](https://pubmed.ncbi.nlm.nih.gov/2013477/)
56. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? *J Hypertens* 2006; 24:243–256. doi: [10.1097/01.hjh.0000202812.72341.99](https://doi.org/10.1097/01.hjh.0000202812.72341.99) PMID: [16508564](https://pubmed.ncbi.nlm.nih.gov/16508564/)
57. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. *Hypertension* 2008; 52:130–136. doi: [10.1161/HYPERTENSIONAHA.107.108845](https://doi.org/10.1161/HYPERTENSIONAHA.107.108845) PMID: [18490518](https://pubmed.ncbi.nlm.nih.gov/18490518/)
58. Boschmann M, Nussberger J, Engeli S, Danser AH, Yeh CM, Prescott MF, et al. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. *J Hypertens* 2012; 30:561–566. doi: [10.1097/HJH.0b013e32834f6b43](https://doi.org/10.1097/HJH.0b013e32834f6b43) PMID: [22278138](https://pubmed.ncbi.nlm.nih.gov/22278138/)
59. Navis G, de Jong PE, Donker AJ, van der Hem GK, de Zeeuw D. Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. *Kidney Int* 1987; 31:815–819. PMID: [3033389](https://pubmed.ncbi.nlm.nih.gov/3033389/)
60. Pechere-Bertschi A, Maillard M, Stalder H, Bischof P, Fathi M, Brunner HR, et al. Renal hemodynamic and tubular responses to salt in women using oral contraceptives. *Kidney Int* 2003; 64:1374–1380. doi: [10.1046/j.1523-1755.2003.00239.x](https://doi.org/10.1046/j.1523-1755.2003.00239.x) PMID: [12969156](https://pubmed.ncbi.nlm.nih.gov/12969156/)

61. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. *Circulation* 1997; 95:39–45. PMID: [8994414](https://pubmed.ncbi.nlm.nih.gov/8994414/)